Cargando…

The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model

PURPOSE: Adenoid hypertrophy (AH) is common among young children. Adenoid-based surgery and drug therapy could be applied for symptomatic AH patients, yet the treatment decision is difficult to make due to the diverse cost and efficacy between these two treatments. METHODS: A Markov simulation model...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Han, Huang, Jinqiang, Liu, Weifeng, Dai, Zihao, Peng, Sui, Peng, Zhenwei, Liang, Ruiming, Ma, Renqiang, Wen, Yihui, Li, Jian, Wen, Weiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028839/
https://www.ncbi.nlm.nih.gov/pubmed/31782019
http://dx.doi.org/10.1007/s11136-019-02374-8
_version_ 1783499054023442432
author Xiao, Han
Huang, Jinqiang
Liu, Weifeng
Dai, Zihao
Peng, Sui
Peng, Zhenwei
Liang, Ruiming
Ma, Renqiang
Wen, Yihui
Li, Jian
Wen, Weiping
author_facet Xiao, Han
Huang, Jinqiang
Liu, Weifeng
Dai, Zihao
Peng, Sui
Peng, Zhenwei
Liang, Ruiming
Ma, Renqiang
Wen, Yihui
Li, Jian
Wen, Weiping
author_sort Xiao, Han
collection PubMed
description PURPOSE: Adenoid hypertrophy (AH) is common among young children. Adenoid-based surgery and drug therapy could be applied for symptomatic AH patients, yet the treatment decision is difficult to make due to the diverse cost and efficacy between these two treatments. METHODS: A Markov simulation model was designed to estimate the cost-effectiveness (CE) of the adenoid-based surgery and the drug therapy for symptomatic AH patients. Transition probabilities, costs and utilities were extracted from early researches and expert opinions. Simulations using two set of parameter inputs for China and the USA were performed. Primary outcome was cost per QALY gained over a 6-year period. Deterministic and probabilistic sensitivity analyses were also conducted. RESULTS: The utility for the surgery group and the drug group were 4.10 quality-adjusted life years (QALYs) and 3.58 QALYs, respectively. The cost of the surgery group was more than that of the drug group using model parameters specific to China ($1069.0 vs. $753.7) but was less for the USA ($1994.4 vs. $3977.7). Surgery was dominant over drug therapy when US specific parameters were used. Surgery group had an ICER of $604.0 per QALY when parameters specific to China was used. CONCLUSION: Surgery is cost-effective in the simulations for both China and the USA at WTP thresholds of $9633.1 and $62,517.5, respectively. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11136-019-02374-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7028839
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-70288392020-03-03 The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model Xiao, Han Huang, Jinqiang Liu, Weifeng Dai, Zihao Peng, Sui Peng, Zhenwei Liang, Ruiming Ma, Renqiang Wen, Yihui Li, Jian Wen, Weiping Qual Life Res Article PURPOSE: Adenoid hypertrophy (AH) is common among young children. Adenoid-based surgery and drug therapy could be applied for symptomatic AH patients, yet the treatment decision is difficult to make due to the diverse cost and efficacy between these two treatments. METHODS: A Markov simulation model was designed to estimate the cost-effectiveness (CE) of the adenoid-based surgery and the drug therapy for symptomatic AH patients. Transition probabilities, costs and utilities were extracted from early researches and expert opinions. Simulations using two set of parameter inputs for China and the USA were performed. Primary outcome was cost per QALY gained over a 6-year period. Deterministic and probabilistic sensitivity analyses were also conducted. RESULTS: The utility for the surgery group and the drug group were 4.10 quality-adjusted life years (QALYs) and 3.58 QALYs, respectively. The cost of the surgery group was more than that of the drug group using model parameters specific to China ($1069.0 vs. $753.7) but was less for the USA ($1994.4 vs. $3977.7). Surgery was dominant over drug therapy when US specific parameters were used. Surgery group had an ICER of $604.0 per QALY when parameters specific to China was used. CONCLUSION: Surgery is cost-effective in the simulations for both China and the USA at WTP thresholds of $9633.1 and $62,517.5, respectively. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11136-019-02374-8) contains supplementary material, which is available to authorized users. Springer International Publishing 2019-11-28 2020 /pmc/articles/PMC7028839/ /pubmed/31782019 http://dx.doi.org/10.1007/s11136-019-02374-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Xiao, Han
Huang, Jinqiang
Liu, Weifeng
Dai, Zihao
Peng, Sui
Peng, Zhenwei
Liang, Ruiming
Ma, Renqiang
Wen, Yihui
Li, Jian
Wen, Weiping
The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model
title The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model
title_full The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model
title_fullStr The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model
title_full_unstemmed The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model
title_short The cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a Markov model
title_sort cost-effectiveness analysis of drug therapy versus surgery for symptomatic adenoid hypertrophy by a markov model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028839/
https://www.ncbi.nlm.nih.gov/pubmed/31782019
http://dx.doi.org/10.1007/s11136-019-02374-8
work_keys_str_mv AT xiaohan thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT huangjinqiang thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT liuweifeng thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT daizihao thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT pengsui thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT pengzhenwei thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT liangruiming thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT marenqiang thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT wenyihui thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT lijian thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT wenweiping thecosteffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT xiaohan costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT huangjinqiang costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT liuweifeng costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT daizihao costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT pengsui costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT pengzhenwei costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT liangruiming costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT marenqiang costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT wenyihui costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT lijian costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel
AT wenweiping costeffectivenessanalysisofdrugtherapyversussurgeryforsymptomaticadenoidhypertrophybyamarkovmodel